2022-06-07 |
Gould Robert J |
director |
86,523.0 |
M-Exempt |
D |
71,435.0 |
7.84 |
560,050.40 |
|
2022-06-07 |
Gould Robert J |
director |
506,630.0 |
S-Sale |
D |
71,435.0 |
8.09 |
577,894.86 |
|
2022-06-07 |
Gould Robert J |
director |
578,065.0 |
M-Exempt |
A |
71,435.0 |
7.84 |
560,050.40 |
|
2022-06-06 |
Gould Robert J |
director |
157,958.0 |
M-Exempt |
D |
24,382.0 |
7.84 |
191,154.88 |
|
2022-06-06 |
Gould Robert J |
director |
182,340.0 |
M-Exempt |
D |
25,551.0 |
7.84 |
200,319.84 |
|
2022-06-06 |
Gould Robert J |
director |
207,891.0 |
M-Exempt |
D |
16,689.0 |
7.84 |
130,841.76 |
|
2022-06-06 |
Gould Robert J |
director |
506,630.0 |
S-Sale |
D |
24,382.0 |
8.10 |
197,591.73 |
|
2022-06-06 |
Gould Robert J |
director |
531,012.0 |
M-Exempt |
A |
24,382.0 |
7.84 |
191,154.88 |
|
2022-06-03 |
Gould Robert J |
director |
506,630.0 |
S-Sale |
D |
25,551.0 |
7.95 |
203,056.35 |
|
2022-06-03 |
Gould Robert J |
director |
532,181.0 |
M-Exempt |
A |
25,551.0 |
7.84 |
200,319.84 |
|
2022-06-02 |
Gould Robert J |
director |
506,630.0 |
S-Sale |
D |
16,689.0 |
7.92 |
132,161.86 |
|
2022-06-02 |
Gould Robert J |
director |
523,319.0 |
M-Exempt |
A |
16,689.0 |
7.84 |
130,841.76 |
|
2022-05-06 |
Tourangeau Greg |
officer: Controller |
6,500.0 |
A-Award |
A |
6,500.0 |
8.63 |
56,095.00 |
|
2022-05-06 |
Tourangeau Greg |
officer: Controller |
16,202.0 |
A-Award |
A |
3,250.0 |
0.00 |
0.00 |
|
2022-04-07 |
Gould Robert J |
director |
224,580.0 |
M-Exempt |
D |
5,631.0 |
7.84 |
44,147.04 |
|
2022-04-07 |
Gould Robert J |
director |
506,630.0 |
S-Sale |
D |
5,631.0 |
24.02 |
135,228.46 |
|
2022-04-07 |
Gould Robert J |
director |
512,261.0 |
M-Exempt |
A |
5,631.0 |
7.84 |
44,147.04 |
|
2022-04-05 |
Gould Robert J |
director |
230,211.0 |
M-Exempt |
D |
52,552.0 |
7.84 |
412,007.68 |
|
2022-04-05 |
Gould Robert J |
director |
282,763.0 |
M-Exempt |
D |
7,235.0 |
7.84 |
56,722.40 |
|
2022-04-05 |
Gould Robert J |
director |
289,998.0 |
M-Exempt |
D |
34,464.0 |
7.84 |
270,197.76 |
|
2022-04-05 |
Gould Robert J |
director |
506,630.0 |
S-Sale |
D |
52,552.0 |
24.26 |
1,274,774.88 |
|
2022-04-05 |
Gould Robert J |
director |
559,182.0 |
M-Exempt |
A |
52,552.0 |
7.84 |
412,007.68 |
|
2022-04-04 |
Gould Robert J |
director |
506,630.0 |
S-Sale |
D |
7,235.0 |
24.02 |
173,749.25 |
|
2022-04-04 |
Gould Robert J |
director |
513,865.0 |
M-Exempt |
A |
7,235.0 |
7.84 |
56,722.40 |
|
2022-04-01 |
Gould Robert J |
director |
506,630.0 |
S-Sale |
D |
34,464.0 |
24.03 |
828,159.58 |
|
2022-04-01 |
Gould Robert J |
director |
541,094.0 |
M-Exempt |
A |
34,464.0 |
7.84 |
270,197.76 |
|
2022-01-19 |
Oltmans Curtis Gale |
officer: SVP, General Counsel |
60,000.0 |
A-Award |
A |
60,000.0 |
12.69 |
761,400.00 |
|
2022-01-19 |
Morabito Christopher |
officer: Chief Medical Officer |
59,744.0 |
A-Award |
A |
59,744.0 |
12.69 |
758,151.36 |
|
2022-01-19 |
Stuart Bryan |
director, officer: President & Chief Executive Officer |
340,000.0 |
A-Award |
A |
340,000.0 |
12.69 |
4,314,600.00 |
|
2022-01-19 |
Dunn Judith |
officer: President, Research & Development |
140,890.0 |
A-Award |
A |
140,890.0 |
12.69 |
1,787,894.10 |
|
2022-01-19 |
Thomson Peter G. |
officer: VP Finance & Accounting |
40,000.0 |
A-Award |
A |
40,000.0 |
12.69 |
507,600.00 |
|
2022-01-03 |
Rajavelu Esther |
officer: Chief Financial Officer |
200,000.0 |
A-Award |
A |
200,000.0 |
17.82 |
3,564,000.00 |
|
2021-12-17 |
Oltmans Curtis Gale |
officer: SVP, General Counsel |
1,248.0 |
G-Gift |
D |
1,088.0 |
0.00 |
0.00 |
|
2021-12-08 |
Banks Sonja |
director |
30,000.0 |
A-Award |
A |
30,000.0 |
15.73 |
471,900.00 |
|
2021-11-10 |
LEVIN MARK J |
director, 10 percent owner |
3,962,202.0 |
J-Other |
D |
1,000,000.0 |
0.00 |
0.00 |
|
2021-11-10 |
Third Rock Ventures III, L.P. |
10 percent owner |
3,962,202.0 |
J-Other |
D |
1,000,000.0 |
0.00 |
0.00 |
|
2021-09-22 |
LEVIN MARK J |
director, 10 percent owner |
4,962,202.0 |
J-Other |
D |
1,000,000.0 |
0.00 |
0.00 |
|
2021-09-22 |
Third Rock Ventures III, L.P. |
10 percent owner |
4,962,202.0 |
J-Other |
D |
1,000,000.0 |
0.00 |
0.00 |
|
2021-08-11 |
Stuart Bryan |
officer: Chief Operating Officer |
28,000.0 |
M-Exempt |
A |
28,000.0 |
23.75 |
665,000.00 |
|
2021-08-11 |
Stuart Bryan |
officer: Chief Operating Officer |
0.0 |
S-Sale |
D |
28,000.0 |
23.75 |
665,000.00 |
|
2021-08-11 |
Stuart Bryan |
officer: Chief Operating Officer |
243,571.0 |
M-Exempt |
D |
28,000.0 |
23.75 |
665,000.00 |
|
2021-08-10 |
Stuart Bryan |
officer: Chief Operating Officer |
32,000.0 |
M-Exempt |
A |
32,000.0 |
7.84 |
250,880.00 |
|
2021-08-10 |
Stuart Bryan |
officer: Chief Operating Officer |
0.0 |
S-Sale |
D |
32,000.0 |
7.84 |
250,880.00 |
|
2021-08-10 |
Stuart Bryan |
officer: Chief Operating Officer |
271,571.0 |
M-Exempt |
D |
32,000.0 |
7.84 |
250,880.00 |
|
2021-08-10 |
Moxham Christopher |
officer: Chief Scientific Officer |
20,714.0 |
M-Exempt |
A |
20,714.0 |
7.84 |
162,397.76 |
|
2021-08-10 |
Moxham Christopher |
officer: Chief Scientific Officer |
72,501.0 |
M-Exempt |
D |
31,071.0 |
18.00 |
559,278.00 |
|
2021-08-10 |
Moxham Christopher |
officer: Chief Scientific Officer |
0.0 |
S-Sale |
D |
20,714.0 |
7.84 |
162,397.76 |
|
2021-08-10 |
Moxham Christopher |
officer: Chief Scientific Officer |
31,071.0 |
M-Exempt |
A |
31,071.0 |
18.00 |
559,278.00 |
|
2021-08-10 |
Moxham Christopher |
officer: Chief Scientific Officer |
103,572.0 |
M-Exempt |
D |
20,714.0 |
7.84 |
162,397.76 |
|
2021-06-28 |
GERAGHTY JAMES A |
director |
90,714.0 |
P-Purchase |
A |
10,000.0 |
9.16 |
91,600.00 |
|
2021-06-28 |
Morabito Christopher |
officer: Chief Medical Officer |
1,100.0 |
P-Purchase |
A |
1,100.0 |
9.16 |
10,076.00 |
|
2021-06-28 |
Oltmans Curtis Gale |
officer: SVP, General Counsel |
1,088.0 |
P-Purchase |
A |
1,088.0 |
9.01 |
9,802.88 |
|
2021-06-28 |
Thomson Peter G. |
officer: VP Finance & Accounting |
2,300.0 |
P-Purchase |
A |
2,300.0 |
9.00 |
20,700.00 |
|
2021-06-09 |
GERAGHTY JAMES A |
director |
15,000.0 |
A-Award |
A |
15,000.0 |
8.85 |
132,750.00 |
|
2021-06-09 |
LEVIN MARK J |
director, 10 percent owner |
15,000.0 |
A-Award |
A |
15,000.0 |
8.85 |
132,750.00 |
|
2021-06-09 |
Haviland Kate |
director |
15,000.0 |
A-Award |
A |
15,000.0 |
8.85 |
132,750.00 |
|
2021-06-09 |
Dorton Katina |
director |
15,000.0 |
A-Award |
A |
15,000.0 |
8.85 |
132,750.00 |
|
2021-06-09 |
Ezekowitz Alan |
director |
15,000.0 |
A-Award |
A |
15,000.0 |
8.85 |
132,750.00 |
|
2021-06-09 |
Collins James J. |
director |
15,000.0 |
A-Award |
A |
15,000.0 |
8.85 |
132,750.00 |
|
2021-05-10 |
Morabito Christopher |
officer: Chief Medical Officer |
163,000.0 |
A-Award |
A |
163,000.0 |
10.01 |
1,631,630.00 |
|
2021-04-01 |
Dunn Judith |
officer: See Remarks |
215,000.0 |
A-Award |
A |
215,000.0 |
12.00 |
2,580,000.00 |
|
2021-03-31 |
Stuart Bryan |
officer: Chief Operating Officer |
350,000.0 |
A-Award |
A |
350,000.0 |
11.78 |
4,123,000.00 |
|
2021-03-16 |
Gould Robert J |
director, officer: See Remarks |
506,630.0 |
S-Sale |
D |
789.0 |
12.43 |
9,805.61 |
|
2021-03-15 |
Gould Robert J |
director, officer: See Remarks |
507,419.0 |
S-Sale |
D |
9,211.0 |
12.13 |
111,772.72 |
|
2021-02-22 |
Thomson Peter G. |
officer: VP Finance & Accounting |
15,212.0 |
S-Sale |
D |
5,000.0 |
7.84 |
39,200.00 |
|
2021-02-22 |
Thomson Peter G. |
officer: VP Finance & Accounting |
50,471.0 |
M-Exempt |
D |
5,000.0 |
7.84 |
39,200.00 |
|
2021-02-22 |
Thomson Peter G. |
officer: VP Finance & Accounting |
20,212.0 |
M-Exempt |
A |
5,000.0 |
7.84 |
39,200.00 |
|
2021-02-16 |
Gould Robert J |
director, officer: See Remarks |
516,630.0 |
S-Sale |
D |
1,673.0 |
14.56 |
24,367.08 |
|
2021-02-16 |
Gould Robert J |
director, officer: See Remarks |
518,303.0 |
S-Sale |
D |
6,542.0 |
14.19 |
92,830.33 |
|
2021-02-08 |
Moxham Christopher |
officer: Chief Scientific Officer |
100,000.0 |
A-Award |
A |
100,000.0 |
12.60 |
1,260,000.00 |
|
2021-02-02 |
Gould Robert J |
director, officer: See Remarks |
269,390.0 |
A-Award |
A |
269,390.0 |
11.33 |
3,052,188.70 |
|
2021-01-25 |
Thomson Peter G. |
officer: VP Finance & Accounting |
40,000.0 |
A-Award |
A |
40,000.0 |
13.09 |
523,600.00 |
|
2021-01-25 |
Stuart Bryan |
officer: Chief Operating Officer |
134,376.0 |
A-Award |
A |
134,376.0 |
13.09 |
1,758,981.84 |
|
2021-01-21 |
Thomson Peter G. |
officer: VP Finance & Accounting |
15,212.0 |
S-Sale |
D |
6,607.0 |
14.00 |
92,498.00 |
|
2021-01-20 |
Gould Robert J |
director, officer: See Remarks |
524,845.0 |
S-Sale |
D |
10,000.0 |
12.08 |
120,826.00 |
|
2020-12-03 |
Oltmans Curtis Gale |
officer: SVP, General Counsel |
153,600.0 |
A-Award |
A |
153,600.0 |
11.82 |
1,815,552.00 |
|
2020-12-03 |
Ezekowitz Alan |
director |
15,000.0 |
A-Award |
A |
15,000.0 |
11.82 |
177,300.00 |
|
2020-09-14 |
Wallace Owen B. |
officer: Chief Scientific Officer |
133,438.0 |
M-Exempt |
A |
6,350.0 |
7.84 |
49,784.00 |
|
2020-09-14 |
Wallace Owen B. |
officer: Chief Scientific Officer |
75,592.0 |
M-Exempt |
D |
6,350.0 |
7.84 |
49,784.00 |
|
2020-07-08 |
Gould Robert J |
director, officer: See Remarks |
534,845.0 |
S-Sale |
D |
2,500.0 |
20.00 |
50,000.00 |
|
2020-07-08 |
Wallace Owen B. |
officer: Chief Scientific Officer |
130,039.0 |
M-Exempt |
A |
2,951.0 |
7.84 |
23,135.84 |
|
2020-07-08 |
Wallace Owen B. |
officer: Chief Scientific Officer |
127,088.0 |
S-Sale |
D |
2,951.0 |
7.84 |
23,135.84 |
|
2020-07-08 |
Wallace Owen B. |
officer: Chief Scientific Officer |
81,942.0 |
M-Exempt |
D |
2,951.0 |
7.84 |
23,135.84 |
|
2020-07-01 |
Cadavid Diego |
officer: SVP Clinical Development |
65,714.0 |
S-Sale |
D |
1,071.0 |
18.30 |
19,599.30 |
|
2020-06-30 |
Wallace Owen B. |
officer: Chief Scientific Officer |
127,229.0 |
M-Exempt |
A |
141.0 |
7.84 |
1,105.44 |
|
2020-06-30 |
Wallace Owen B. |
officer: Chief Scientific Officer |
127,088.0 |
S-Sale |
D |
141.0 |
7.84 |
1,105.44 |
|
2020-06-30 |
Wallace Owen B. |
officer: Chief Scientific Officer |
84,893.0 |
M-Exempt |
D |
141.0 |
7.84 |
1,105.44 |
|
2020-06-25 |
Gould Robert J |
director, officer: See Remarks |
537,345.0 |
S-Sale |
D |
2,500.0 |
20.80 |
51,992.00 |
|
2020-06-25 |
Cadavid Diego |
officer: SVP Clinical Development |
68,244.0 |
M-Exempt |
A |
1,459.0 |
4.83 |
7,046.97 |
|
2020-06-25 |
Cadavid Diego |
officer: SVP Clinical Development |
66,785.0 |
S-Sale |
D |
1,459.0 |
4.83 |
7,046.97 |
|
2020-06-25 |
Cadavid Diego |
officer: SVP Clinical Development |
12,277.0 |
M-Exempt |
D |
1,459.0 |
4.83 |
7,046.97 |
|
2020-06-11 |
GERAGHTY JAMES A |
director |
9,285.0 |
A-Award |
A |
9,285.0 |
17.63 |
163,694.55 |
|
2020-06-11 |
LEVIN MARK J |
director, 10 percent owner |
9,285.0 |
A-Award |
A |
9,285.0 |
17.63 |
163,694.55 |
|
2020-06-11 |
Collins James J. |
director |
9,285.0 |
A-Award |
A |
9,285.0 |
17.63 |
163,694.55 |
|
2020-06-11 |
Ezekowitz Alan |
director |
9,285.0 |
A-Award |
A |
9,285.0 |
17.63 |
163,694.55 |
|
2020-06-11 |
Haviland Kate |
director |
9,285.0 |
A-Award |
A |
9,285.0 |
17.63 |
163,694.55 |
|
2020-06-10 |
Cadavid Diego |
officer: SVP Clinical Development |
66,785.0 |
S-Sale |
D |
401.0 |
4.83 |
1,936.83 |
|
2020-06-10 |
Cadavid Diego |
officer: SVP Clinical Development |
13,736.0 |
M-Exempt |
D |
401.0 |
4.83 |
1,936.83 |
|
2020-06-10 |
Cadavid Diego |
officer: SVP Clinical Development |
67,186.0 |
M-Exempt |
A |
401.0 |
4.83 |
1,936.83 |
|
2020-06-09 |
Gould Robert J |
director, officer: See Remarks |
539,845.0 |
S-Sale |
D |
156.0 |
20.00 |
3,120.00 |
|